Diabetes & Associated Metabolic Conditions: 2018 Drug Development Pipeline Review - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 6, 2018--The “Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.
This report provides an overview of the pipeline landscape for diabetes and associated metabolic conditions. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for type I diabetes, type II diabetes, hyperinsulinemia and hyperglycemia, and features dormant and discontinued products.
Diabetes refers to a group of metabolic diseases that result from defects in insulin secretion, insulin action or both of these. Type I diabetes is an autoimmune disease in which the pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. There are 263 products in development for this indication.
Type 2 diabetes, however, results from a combination of resistance to insulin action and an inadequate compensatory insulin secretory response. Type 2 diabetes is more closely related to lifestyle choices such as diet and exercise habits than type I diabetes, with the majority of patients being overweight or obese. There are 574 products in development for this indication.
Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. There are 10 products in development for this indication.
Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. There are seven products in development for this indication.
Molecular targets acted on by products in development for diabetes and associated metabolic conditions include the insulin receptor, glucagon-like peptide 1 (GLP-1) receptor, glucagon receptor and glucokinase. Companies operating in this pipeline space include Novo Nordisk, Eli Lilly and Zealand Pharma.
Key Topics Covered
1 Table of Contents
3 Therapeutics Development
4 Therapeutics Assessment
5 Companies Involved in Therapeutics Development
6 Dormant Projects
7 Discontinued Products
8 Product Development Milestones
Companies FeaturedAdocia SAS Aegis Therapeutics LLC AFFiRiS AG Braasch Biotech LLC Bristol-Myers Squibb Co BTB Pharma AB CymaBay Therapeutics Inc Daewoong Pharmaceutical Co Ltd DiscoveryBiomed Inc DNJ Pharma Inc Evotec AG F. Hoffmann-La Roche Ltd Fate Therapeutics Inc Gilead Sciences Inc GlaxoSmithKline Plc Glucox Biotech AB Hanmi Pharmaceuticals Co Ltd Leading BioSciences Inc PharmaCyte Biotech Inc PharmaIN Corp Pharmasum Therapeutics AS Pila Pharma AB Poxel SA Prometheon Pharma LLC Sirona Biochem Corp SJT Molecular Research SL SK Chemicals Co Ltd Sotio AS Sprint Bioscience AB Sumitomo Dainippon Pharma Co Ltd Suzuken Co Ltd XuanZhu Pharma Co Ltd Zealand Pharma AS and many more...
For more information about this report visit https://www.researchandmarkets.com/research/b7kk2b/diabetes_and?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180706005416/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Drug Discovery,Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/06/2018 03:58 PM/DISC: 07/06/2018 03:58 PM